Clinical Trials Browser

INDUSTRY × Melanoma × eprenetapopt × Clear all

NCT03391050 2019-07-31

A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma

Phase 1/2 Terminated

Melanoma, Neoplasm Metastasis, Skin Neoplasms